Development of a Neuroprotective Peptide That Preserves Survival Pathways by Preventing Kidins220/ARMS Calpain Processing Induced by Excitotoxicity
Overview
General Medicine
Authors
Affiliations
Kinase D-interacting substrate of 220 kDa (Kidins220), also known as ankyrin repeat-rich membrane spanning (ARMS), has a central role in the coordination of receptor crosstalk and the integration of signaling pathways essential for neuronal differentiation, survival and function. This protein is a shared downstream effector for neurotrophin- and ephrin-receptors signaling that also interacts with the N-methyl-d-aspartate type of glutamate receptors (NMDARs). Failures in neurotrophic support and glutamate signaling are involved in pathologies related to excitotoxicity and/or neurodegeneration, where different components of these dynamic protein complexes result altered by a combination of mechanisms. In the case of Kidins220/ARMS, overactivation of NMDARs in excitotoxicity and cerebral ischemia triggers its downregulation, which contributes to neuronal death. This key role in neuronal life/death decisions encouraged us to investigate Kidins220/ARMS as a novel therapeutic target for neuroprotection. As the main mechanism of Kidins220/ARMS downregulation in excitotoxicity is proteolysis by calpain, we decided to develop cell-penetrating peptides (CPPs) that could result in neuroprotection by interference of this processing. To this aim, we first analyzed in detail Kidins220/ARMS cleavage produced in vitro and in vivo, identifying a major calpain processing site in its C-terminal region (between amino acids 1669 and 1670) within a sequence motif highly conserved in vertebrates. Then, we designed a 25-amino acids CPP (Tat-K) containing a short Kidins220/ARMS sequence enclosing the identified calpain site (amino acids 1668-1681) fused to the HIV-1 Tat protein basic domain, able to confer membrane permeability to attached cargoes. Transduction of cortical neurons with Tat-K reduced Kidins220/ARMS calpain processing in a dose- and time-dependent manner upon excitotoxic damage and allowed preservation of the activity of pERK1/2 and pCREB, signaling molecules central to neuronal survival and functioning. Importantly, these effects were associated to a significant increase in neuronal viability. This Kidins220/ARMS-derived peptide merits further research to develop novel neuroprotective therapies for excitotoxicity-associated pathologies.
Fernandez-Albarral J, Simon-Garcia A, Salobrar-Garcia E, Salazar J, Lopez-Menendez C, Pajuelo L Fluids Barriers CNS. 2025; 22(1):16.
PMID: 39939990 PMC: 11823095. DOI: 10.1186/s12987-025-00626-z.
Fonseca-Gomes J, Costa-Coelho T, Ferreira-Manso M, Inteiro-Oliveira S, Vaz S, Aleman-Serrano N Mol Ther. 2024; 32(10):3372-3401.
PMID: 39205389 PMC: 11489560. DOI: 10.1016/j.ymthe.2024.08.022.
Del Puerto A, Lopez-Fonseca C, Simon-Garcia A, Marti-Prado B, Barrios-Munoz A, Pose-Utrilla J Cell Death Dis. 2023; 14(8):500.
PMID: 37542079 PMC: 10403621. DOI: 10.1038/s41419-023-05995-7.
Kidins220 deficiency causes ventriculomegaly via SNX27-retromer-dependent AQP4 degradation.
Del Puerto A, Pose-Utrilla J, Simon-Garcia A, Lopez-Menendez C, Jimenez A, Porlan E Mol Psychiatry. 2021; 26(11):6411-6426.
PMID: 34002021 PMC: 8760065. DOI: 10.1038/s41380-021-01127-9.
Meloni B, Mastaglia F, Knuckey N Front Neurol. 2020; 11:108.
PMID: 32158425 PMC: 7052017. DOI: 10.3389/fneur.2020.00108.